XML 46 R37.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) |  |  |  | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Aug. 05, 2019 USD ($) | Aug. 05, 2019 EUR (€) | Jun. 06, 2019 EUR (€) | Aug. 06, 2018 USD ($) $ / shares shares | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Aug. 31, 2019 USD ($) | Jan. 02, 2019 USD ($)
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Federal insurance limits |  |  |  |  | $ 250,000 |  |  |  |
Number of issued patents domestic. |  |  |  |  | 29 |  |  |  |
Number of issued patents foreign |  |  |  |  | 30 |  |  |  |
Stock Issued During Period, Value, New Issues |  |  |  |  | $ 77,031,258 | $ 89,907,797 | $ 68,572,635 |  |
Number of operating segments |  |  |  |  | 1 |  |  |  |
Advertising costs |  |  |  |  | $ 9,045,571 | 1,682,746 | $ 448,288 |  |
Right of use asset |  |  |  |  | 10,109,154 |  |  | $ 7,400,000 |
Lease liability |  |  |  |  | $ 10,646,588 |  |  | $ 7,200,000 |
Accounting Standards Update 2016-02 [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Right of use asset |  |  |  |  |  |  |  |  | $ 3,800,000
Lease liability |  |  |  |  |  |  |  |  | $ 4,100,000
License Agreement Theramex |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Cash upfront payment received | $ 15,506,400 | € 14,000,000 |  |  |  |  |  |  |
Subscription Agreement Knight [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  |  | 3,921,568 |  |  |  |  |
Sale of Stock, Price Per Share | $ / shares |  |  |  | $ 5.10 |  |  |  |  |
Stock Issued During Period, Value, New Issues |  |  |  | $ 20,000,000 |  |  |  |  |
Vitamins and IMVEXXY [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Shelf life of prescription products following product expiration |  |  |  |  | 24 months |  |  |  |
BIJUVA and ANNOVERA [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Shelf life of prescription products following product expiration |  |  |  |  | 18 months |  |  |  |
BIJUVA and ANNOVERA [Member] | License Agreement Theramex |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Quarterly royalty payments percentage |  |  | 5.00% |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Return period of unsalable prescription products |  |  |  |  | 6 months |  |  |  |
Minimum [Member] | License Agreement Theramex |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Sales milestone | € |  |  | € 25,000,000 |  |  |  |  |  |
Maximum [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Return period of unsalable prescription products |  |  |  |  | 12 months |  |  |  |
Maximum [Member] | License Agreement Theramex |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Regulatory milestone payments | € |  |  | 2,000,000 |  |  |  |  |  |
Sales milestone payment | € |  |  | 27,500,000 |  |  |  |  |  |
Sales milestone | € |  |  | € 100,000,000 |  |  |  |  |  |
Land and Building [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  | 3 years |  |  |  |
Land and Building [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  | 7 years |  |  |  |
Software and Software Development Costs [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  | 5 years |  |  |  |
Software and Software Development Costs [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Useful life of assets |  |  |  |  | 7 years |  |  |  |
Accounts Receivable [Member] | Customer A [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Concentration risk |  |  |  |  | 36.00% | 42.00% |  |  |
Accounts Receivable [Member] | Customer B [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Concentration risk |  |  |  |  | 21.00% | 24.00% |  |  |
Accounts Receivable [Member] | Customer C [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Concentration risk |  |  |  |  | 16.00% | 13.00% |  |  |
Accounts Receivable [Member] | Customer D [Member] |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |
Concentration risk |  |  |  |  | 11.00% |  |  |  |

X
- Definition Annual net sale milestones in the Territory per license agreement. + References No definition available. + Details
Name: | txmd_AnnualNetSalesMilestone
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from license agreement. + References No definition available. + Details
Name: | txmd_CashUpfrontPaymentReceived
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of issued patents domestic. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatentsDomestic
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of issued patents foreign. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatentsForeign
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of quarterly royalty payments on net sales which the company is entitled to receive. + References No definition available. + Details
Name: | txmd_QuarterlyRoyaltyPaymentsPercentage
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets. + References No definition available. + Details
Name: | txmd_RegulatoryMilestoneAdditionalPayment
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Period the company accepts returns of unsalable prescription products from customers following product expiration. + References No definition available. + Details
Name: | txmd_ReturnPeriodOfUnsalablePrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of sales milestone payments per licensing agreement. + References No definition available. + Details
Name: | txmd_SalesMilestonePaymentsInTranches
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Period shelf life of prescription products from date of manufacture. + References No definition available. + Details
Name: | txmd_ShelfLifeOfPrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 35 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848 + Details
Name: | us-gaap_AdvertisingExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. + References No definition available. + Details
Name: | us-gaap_CashFDICInsuredAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + References No definition available. + Details
Name: | us-gaap_NumberOfReportableSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Present value of lessee's discounted obligation for lease payments from operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details
Name: | us-gaap_OperatingLeaseLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of lessee's right to use underlying asset under operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details
Name: | us-gaap_OperatingLeaseRightOfUseAsset
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |